介入或外科肺动脉瓣置换后感染性心内膜炎的手术治疗
该单中心回顾性研究纳入2013年3月至2020年7月确诊感染性心内膜炎的20例先天性心脏病患者,感染管道包括11枚Melody、5枚Contegra、3枚同种移植物和1枚Matrix P Plus。所有患者均手术切除感染人工材料并植入肺动脉同种移植物,全部存活且无感染出院,随访中无死亡或复发。
要点
- 感染性人工肺动脉瓣/管道应积极手术切除感染材料并重建右室流出道
- 20例患者均存活出院且无感染,随访无死亡或复发
- 怀疑感染性心内膜炎应早期转诊手术,避免右心衰和脓毒栓塞等后遗症
核心结论
- 介入肺动脉瓣假体和右室-肺动脉管道感染性心内膜炎的外科治疗是安全有效的治疗理念。
- 怀疑感染性心内膜炎应尽早转诊外科,以避免右心室衰竭、脓毒栓塞、心内扩散和抗生素耐药等后遗症。
研究设计与样本
- 单中心回顾性研究,纳入2013年3月至2020年7月确诊感染性心内膜炎的20例先天性心脏病患者。
- 感染管道包括11枚Melody、5枚Contegra、3枚同种移植物和1枚Matrix P Plus。
- 手术切除右室流出道至肺动脉分叉处全部感染人工材料,肺动脉根切除后植入肺动脉同种移植物作为右室-肺动脉管道。
主要发现
- 所有患者均存活且无感染出院。
- 从管道植入到因感染性心内膜炎手术的平均时间为4.9年(95%CI 3.0-6.9)。
- 中位ICU停留3.0天(95%CI 2.0-4.7),中位住院时间25.0天(95%CI 19.2-42.0)。
- 中位随访204.5天(范围30天至5年),无死亡或复发性心内膜炎。
临床怎么用
- 对介入肺动脉瓣或右室-肺动脉管道植入后怀疑感染性心内膜炎的患者,应早期转诊外科评估。
- 手术策略为彻底切除感染人工材料至肺动脉分叉,并植入肺动脉同种移植物重建右室-肺动脉连接。
局限性
- 单中心回顾性研究,样本量20例,随访时间中位204.5天,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Percutaneous pulmonary valve prostheses and right ventricle-to-pulmonary artery conduits are at risk for infective endocarditis (IE). In children and adults with a congenital heart disease, a pulmonary valve implant is frequently necessary. Prosthetic valve endocarditis is a conservatively barely manageable, serious life-threatening condition. We investigated the results of surgical pulmonary valve replacements in patients with IE. METHODS: A total of 20 patients with congenital heart disease with the definite diagnosis of IE between March 2013 and July 2020 were included in this single institutional, retrospective review. Infected conduits were 11 Melody, 5 Contegra, 3 homografts and 1 Matrix P Plus. All of the infected prosthetic material was removed from the right ventricular outflow tract up to the pulmonary bifurcation. Pulmonary homografts were implanted after pulmonary root resection as right ventricle-to-pulmonary artery conduits. RESULTS: All patients survived and were discharged infection-free. The mean time from the conduit implant to the operation for IE was 4.9 years [95% confidence interval (CI), 3.0-6.9]. The median intensive care unit stay was 3.0 days (95% CI, 2.0-4.7), and the median hospital time was 25.0 days (95% CI, 19.2-42.0). Median follow-up time was 204.5 days (range 30 days to 5 years) without death or recurrent endocarditis. CONCLUSIONS: The surgical treatment of IE of percutaneous pulmonary valve prostheses and right ventricle-to-pulmonary artery conduits is a safe and effective therapeutic concept. Early surgical referral of patients with suspicion of IE should be pursued to avoid sequelae such as right ventricular failure, septic emboli, intracardiac expansion and antibiotic resistance.
引用
- Gierlinger G, Sames-Dolzer E, Kreuzer M, et al. Surgical therapy of infective endocarditis following interventional or surgical pulmonary valve replacement. Eur J Cardiothorac Surg. 2021. PMID: 33668059. doi:10.1093/ejcts/ezab086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。